Investigational drug · Phase 3
barzolvolimab
Also called: CDX-0159
Not approved by FDA. In 7 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, Cold Urticaria.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
7
6 still active
All registered trials
10
Any phase or sponsor naming "barzolvolimab"
First trial start
2023
Jun 1, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "barzolvolimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Spontaneous Urticaria
- Chronic Inducible Urticaria
- Cold Urticaria
- Cold-Induced Urticaria
- Symptomatic Dermographism
- Prurigo Nodularis
- Atopic Dermatitis
- Eosinophilic Esophagitis
Approved drugs for the same conditions: Atopic dermatitis (eczema) · Chronic hives (urticaria) · Eosinophilic esophagitis · Immunology and inflammation · Gastroenterology and liver · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "barzolvolimab" as an intervention, largest first.
- Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous UrticariaPivotal-lookingEnrolling by invitation
Celldex TherapeuticsIndustry
NCT07256392 · 1,370 participants (planned) · Start Nov 25, 2025 · Primary completion Sep 2028
Drug: barzolvolimab · For: Chronic Spontaneous Urticaria
Sites: Birmingham, Alabama; Scottsdale, Arizona; Bakersfield, California · 201 sites in all
- A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)Pivotal-lookingActive, not recruiting
Celldex TherapeuticsIndustry
NCT06455202 · 976 participants · Start Jul 19, 2024 · Primary completion Aug 4, 2026
Drug: barzolvolimab; Matching placebo · For: Chronic Spontaneous Urticaria
Sites: Cullman, Alabama; Litchfield Park, Arizona; Scottsdale, Arizona · 245 sites in all
- A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous UrticariaPivotal-lookingActive, not recruiting
Celldex TherapeuticsIndustry
NCT06445023 · 963 participants · Start Jul 11, 2024 · Primary completion Aug 12, 2026
Drug: barzolvolimab; Matching placebo · For: Chronic Spontaneous Urticaria
Sites: Birmingham, Alabama; Fountain Valley, California; Inglewood, California · 235 sites in all
- A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)Pivotal-lookingRecruiting
Celldex TherapeuticsIndustry
NCT07266402 · 240 participants (planned) · Start Jan 15, 2026 · Primary completion Jun 2028
Drug: Barzolvolimab; Matching Placebo · For: Chronic Inducible Urticaria; Cold Urticaria; Cold-Induced Urticaria and 1 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Bakersfield, California · 72 sites in all
- A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous UrticariaPivotal-lookingCompleted
Celldex TherapeuticsIndustry
NCT05368285 · 208 participants · Start May 19, 2022 · Primary completion Sep 28, 2023
Drug: barzolvolimab; Matching Placebo · For: Chronic Spontaneous Urticaria
Sites: Birmingham, Alabama; Scottsdale, Arizona; Little Rock, Arkansas · 56 sites in all
- A Study of CDX-0159 in Patients With Chronic Inducible UrticariaPivotal-lookingCompleted
Celldex TherapeuticsIndustry
NCT05405660 · 196 participants · Start Jun 28, 2022 · Primary completion Jun 12, 2024
Drug: barzolvolimab; Matching Placebo · For: Chronic Inducible Urticaria
Sites: Birmingham, Alabama; Montgomery, Alabama; Paradise Valley, Arizona · 76 sites in all
- A Study of Barzolvolimab in Patients With Prurigo NodularisPivotal-lookingActive, not recruiting
Celldex TherapeuticsIndustry
NCT06366750 · 140 participants · Start Apr 12, 2024 · Primary completion Mar 17, 2026
Drug: barzolvolimab · For: Prurigo Nodularis
Sites: Birmingham, Alabama; Scottsdale, Arizona; Fremont, California · 72 sites in all
- A Study of Barzolvolimab in Patients With Atopic DermatitisPivotal-lookingActive, not recruiting
Celldex TherapeuticsIndustry
NCT06727552 · 131 participants · Start Dec 18, 2024 · Primary completion May 6, 2026
Drug: Barzolvolimab; Matching placebo · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Beverly Hills, California; Burbank, California · 33 sites in all
Celldex TherapeuticsIndustry
NCT05774184 · 86 participants · Start Jun 1, 2023 · Primary completion Jun 4, 2025
Drug: barzolvolimab; Matching Placebo · For: Eosinophilic Esophagitis
Sites: Birmingham, Alabama; Scottsdale, Arizona; Sun City, Arizona · 45 sites in all
Celldex TherapeuticsIndustry
NCT04944862 · 24 participants · Start Nov 8, 2021 · Primary completion Jul 31, 2023
Drug: CDX-0159; Normal saline · For: Prurigo Nodularis
Sites: Tempe, Arizona; Miami, Florida; Troy, Michigan · 17 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Management of Pediatric Chronic Spontaneous Urticaria: Current Evidence and Emerging Therapies.
Tedeschi M, Buethe MG, Marseglia GL, et al. · Paediatr Drugs 2026
- Beyond Omalizumab: Emerging Biologic and Small Molecule Therapies in Chronic Spontaneous Urticaria.
Kaur S, Kumaran MS, Singh S, et al. · Clin Exp Allergy 2026
- Barzolvolimab: Targeting the effector cell in chronic spontaneous urticaria.
Giannetti MP · J Allergy Clin Immunol 2026
- Differential susceptibility of hair colour changes after barzolvolimab.
Muñoz M, Zhou J, Bonnekoh H, et al. · J Eur Acad Dermatol Venereol 2026
- Randomized dose-finding study of anti-KIT barzolvolimab in patients with chronic spontaneous urticaria.
Metz M, Mitha E, Leflein J, et al. · J Allergy Clin Immunol 2026
- Effectiveness and Safety of Pharmacological Treatments for Chronic Inducible Urticaria: A Narrative Synthesis.
Chatzidimitriou E, Tsiogka E, Tsiogka A, et al. · J Clin Med 2026
Also in development for Chronic Spontaneous Urticaria
- PovorcitinibINCB054707, INCB54707Phase 312 trials
Incyte · Hidradenitis Suppurativa (HS), NonSegmental Vitiligo, Prurigo Nodularis
- LP-003SinglePhase 39 trials
Longbio Pharma · Allergic Asthma, Chronic Spontaneous Urticaria (CSU), Peanut Allergies
- TLL-018Phase 38 trials
Hangzhou Highlightll Pharmaceutical Co., Ltd · Chronic Spontaneous Urticaria (CSU), Rheumatoid Arthritis, Chronic Spontaneous Urticaria
- JYB1904RPT904, ozureprubartPhase 35 trials
Jemincare · Chronic Spontaneous Urticaria, Perennial Allergic Rhinitis, Immune System Diseases
- AK139Phase 26 trials
Akeso · Asthma, Moderate-to-Severe Atopic Dermatitis, Chronic Spontaneous Urticaria
- EVO756Phase 24 trials
Evommune, Inc. · Migraine, Chronic Inducible Urticaria, Atopic Dermatitis
- BLU-808Phase 22 trials
Blueprint Medicines Corporation · Chronic Inducible Urticaria, Chronic Spontaneous Urticaria, Allergic Rhinoconjunctivitis
- BBT001Phase 21 trial
Bambusa Therapeutics · Chronic Spontaneous Urticaria
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.